Sherif M Reda, Sharay E Setti, Andrée-Anne Berthiaume, Wei Wu, Robert W Taylor, Jewel L Johnston, Liana R Stein, Hans J Moebius, Kevin J Church
Positive modulation of hepatocyte growth factor (HGF) signaling may represent a promising therapeutic strategy for Alzheimer's disease (AD) based on its multimodal neurotrophic, neuroprotective, and anti-inflammatory effects addressing the complex pathophysiology of neurodegeneration. Fosgonimeton is a small-molecule positive modulator of the HGF system that has demonstrated neurotrophic and pro-cognitive effects in preclinical models of dementia. Herein, we evaluate the neuroprotective potential of fosgonimeton, or its active metabolite, fosgo-AM, in amyloid-beta (Aβ)-driven preclinical models of AD, providing mechanistic insight into its mode of action...
April 9, 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics